Nordimet

Country: European Union

Language: English

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

Methotrexate

Available from:

Nordic Group B.V.

ATC code:

L04AX03

INN (International Name):

methotrexate

Therapeutic group:

Antineoplastic agents,

Therapeutic area:

Arthritis, Psoriatic, Psoriasis, Arthritis, Juvenile Rheumatoid, Arthritis, Rheumatoid

Therapeutic indications:

Nordimet is indicated for the treatment of:active rheumatoid arthritis in adult patients,polyarthritic forms of severe, active juvenile idiopathic arthritis (JIA), when the response to nonsteroidal anti-inflammatory drugs (NSAIDs) has been inadequate,severe recalcitrant disabling psoriasis, which is not adequately responsive to other forms of therapy such as phototherapy, psoralens and ultraviolet A (PUVA), and retinoids, and severe psoriatic arthritis in adult patients.

Product summary:

Revision: 9

Authorization status:

Authorised

Authorization date:

2016-08-17

Patient Information leaflet

                                135
B. PACKAGE LEAFLET
136
PACKAGE LEAFLET: INFORMATION FOR THE USER
NORDIMET 7.5 MG SOLUTION FOR INJECTION IN PRE-FILLED PEN
NORDIMET 10 MG SOLUTION FOR INJECTION IN PRE-FILLED PEN
NORDIMET 12.5 MG SOLUTION FOR INJECTION IN PRE-FILLED PEN
NORDIMET 15 MG SOLUTION FOR INJECTION IN PRE-FILLED PEN
NORDIMET 17.5 MG SOLUTION FOR INJECTION IN PRE-FILLED PEN
NORDIMET 20 MG SOLUTION FOR INJECTION IN PRE-FILLED PEN
NORDIMET 22.5 MG SOLUTION FOR INJECTION IN PRE-FILLED PEN
NORDIMET 25 MG SOLUTION FOR INJECTION IN PRE-FILLED PEN
methotrexate
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm
them, even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Nordimet is and what it is used for
2.
What you need to know before you use Nordimet
3.
How to use Nordimet
4.
Possible side effects
5.
How to store Nordimet
6.
Contents of the pack and other information
1.
WHAT NORDIMET IS AND WHAT IT IS USED FOR
Nordimet contains the active substance methotrexate which works by:
-
reducing inflammation or swelling, and
- reducing the activity of the immune system (the body’s own defense
mechanism). An
overactive immune system has been linked to inflammatory diseases.
Nordimet is a medicine used to treat a range of inflammatory diseases:
-
active rheumatoid arthritis in adults. Active rheumatoid arthritis is
an inflammatory condition
that affects the joints;
-
severe, active juvenile idiopathic arthritis in five or more joints
(the condition is therefore
called polyarthritic), in patients who have had an inadequate response
to nonsteroidal
anti-inflammatory drugs (NSAIDs);
-
a severe fo
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1
NAME OF THE MEDICINAL PRODUCT
Nordimet 7.5 mg solution for injection in pre-filled pen
Nordimet 10 mg solution for injection in pre-filled pen
Nordimet 12.5 mg solution for injection in pre-filled pen
Nordimet 15 mg solution for injection in pre-filled pen
Nordimet 17.5 mg solution for injection in pre-filled pen
Nordimet 20 mg solution for injection in pre-filled pen
Nordimet 22.5 mg solution for injection in pre-filled pen
Nordimet 25 mg solution for injection in pre-filled pen
Nordimet 7.5 mg solution for injection in pre-filled syringe
Nordimet 10 mg solution for injection in pre-filled syringe
Nordimet 12.5 mg solution for injection in pre-filled syringe
Nordimet 15 mg solution for injection in pre-filled syringe
Nordimet 17.5 mg solution for injection in pre-filled syringe
Nordimet 20 mg solution for injection in pre-filled syringe
Nordimet 22.5 mg solution for injection in pre-filled syringe
Nordimet 25 mg solution for injection in pre-filled syringe
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
One ml of solution contains 25 mg of methotrexate.
Nordimet 7.5 mg solution for injection in pre-filled pen
Each pre-filled pen contains 7.5 mg methotrexate in 0.3 mL
Nordimet 10 mg solution for injection in pre-filled pen
Each pre-filled pen contains 10 mg methotrexate in 0.4 mL
Nordimet 12.5 mg solution for injection in pre-filled pen
Each pre-filled pen contains 12.5 mg methotrexate in 0.5 mL
Nordimet 15 mg solution for injection in pre-filled pen
Each pre-filled pen contains 15 mg methotrexate in 0.6 mL
Nordimet 17.5 mg solution for injection in pre-filled pen
Each pre-filled pen contains 17.5 mg methotrexate in 0.7 mL
Nordimet 20 mg solution for injection in pre-filled pen
Each pre-filled pen contains 20 mg methotrexate in 0.8 mL
Nordimet 22.5 mg solution for injection in pre-filled pen
Each pre-filled pen contains 22.5 mg methotrexate in 0.9 mL
Nordimet 25 mg solution for injection in pre-filled pen
Each pre-filled pen contains 25 mg methotrexate in 1.0 mL
Nordime
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 29-02-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 29-02-2024
Public Assessment Report Public Assessment Report Bulgarian 20-11-2023
Patient Information leaflet Patient Information leaflet Spanish 29-02-2024
Public Assessment Report Public Assessment Report Spanish 20-11-2023
Patient Information leaflet Patient Information leaflet Czech 29-02-2024
Public Assessment Report Public Assessment Report Czech 20-11-2023
Patient Information leaflet Patient Information leaflet Danish 29-02-2024
Public Assessment Report Public Assessment Report Danish 20-11-2023
Patient Information leaflet Patient Information leaflet German 29-02-2024
Public Assessment Report Public Assessment Report German 20-11-2023
Patient Information leaflet Patient Information leaflet Estonian 29-02-2024
Public Assessment Report Public Assessment Report Estonian 20-11-2023
Patient Information leaflet Patient Information leaflet Greek 29-02-2024
Public Assessment Report Public Assessment Report Greek 20-11-2023
Patient Information leaflet Patient Information leaflet French 29-02-2024
Public Assessment Report Public Assessment Report French 20-11-2023
Patient Information leaflet Patient Information leaflet Italian 29-02-2024
Public Assessment Report Public Assessment Report Italian 20-11-2023
Patient Information leaflet Patient Information leaflet Latvian 29-02-2024
Public Assessment Report Public Assessment Report Latvian 20-11-2023
Patient Information leaflet Patient Information leaflet Lithuanian 29-02-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 29-02-2024
Public Assessment Report Public Assessment Report Lithuanian 20-11-2023
Patient Information leaflet Patient Information leaflet Hungarian 29-02-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 29-02-2024
Public Assessment Report Public Assessment Report Hungarian 20-11-2023
Patient Information leaflet Patient Information leaflet Maltese 29-02-2024
Public Assessment Report Public Assessment Report Maltese 20-11-2023
Patient Information leaflet Patient Information leaflet Dutch 29-02-2024
Public Assessment Report Public Assessment Report Dutch 20-11-2023
Patient Information leaflet Patient Information leaflet Polish 29-02-2024
Public Assessment Report Public Assessment Report Polish 20-11-2023
Patient Information leaflet Patient Information leaflet Portuguese 29-02-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 29-02-2024
Public Assessment Report Public Assessment Report Portuguese 20-11-2023
Patient Information leaflet Patient Information leaflet Romanian 29-02-2024
Public Assessment Report Public Assessment Report Romanian 20-11-2023
Patient Information leaflet Patient Information leaflet Slovak 29-02-2024
Public Assessment Report Public Assessment Report Slovak 20-11-2023
Patient Information leaflet Patient Information leaflet Slovenian 29-02-2024
Summary of Product characteristics Summary of Product characteristics Slovenian 29-02-2024
Public Assessment Report Public Assessment Report Slovenian 20-11-2023
Patient Information leaflet Patient Information leaflet Finnish 29-02-2024
Public Assessment Report Public Assessment Report Finnish 20-11-2023
Patient Information leaflet Patient Information leaflet Swedish 29-02-2024
Public Assessment Report Public Assessment Report Swedish 20-11-2023
Patient Information leaflet Patient Information leaflet Norwegian 29-02-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 29-02-2024
Patient Information leaflet Patient Information leaflet Icelandic 29-02-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 29-02-2024
Patient Information leaflet Patient Information leaflet Croatian 29-02-2024
Public Assessment Report Public Assessment Report Croatian 20-11-2023

Search alerts related to this product

View documents history